US Stock MarketDetailed Quotes

ARMP Armata Pharmaceuticals

Watchlist
  • 1.950
  • -0.040-2.01%
Close Feb 14 16:00 ET
70.56MMarket Cap-1.70P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 19, 2024 06:06
    NEWS
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
    Thursday, 19th December at 7:00 am
    Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile
    LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Armata Pharmaceutic...
    Jaguar8
    Jaguar8
    Nov 14, 2024 15:33
    13D
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Innoviva, Inc(85.2%),Innoviva Strategic Opportunities LLC(62.1%)
    Jaguar8
    Jaguar8
    Nov 12, 2024 06:06
    NEWS
    $Armata Pharmaceuticals (ARMP.US)$
    Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
    Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025
    LOS ANGELES, Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology compan...
    Trytosaveabit
    Trytosaveabit
    Aug 14, 2024 05:42
    Watching for data!
    $Armata Pharmaceuticals (ARMP.US)$         The last patient had their final follow-up visit on August 7th, in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. Armata anticipates topline data from the Tailwind study in the second half of 2024.
    2
    Trytosaveabit
    Trytosaveabit
    Jul 30, 2024 06:06
    Update
    $Armata Pharmaceuticals (ARMP.US)$ Reuters· 5 mins ago
    Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding From the U.S. Department of Defense to Support Ongoing Disarm Clinical Trial of AP-SA02
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More
China's asset revaluation sparks debate: What are mooers buying?